XML 103 R30.htm IDEA: XBRL DOCUMENT v3.22.4
Acquisitions of businesses
 12 Months Ended
Dec. 31, 2022
Disclosure of acquisition of businesses [abstract]  
Acquisition of businesses
24. Acquisitions of businesses
Fair value of assets and liabilities arising from acquisitions of businesses:
(USD millions)
2022
2021
2020
Property, plant and equipment
13
26
Right-of-use assets
12
32
Currently marketed products
292
196
Acquired research and development
1 209
262
8 600
Other intangible assets
98
218
Deferred tax assets
56
28
476
Non-current financial and other assets
49
Inventories
84
Trade receivables and financial and other current assets
5
1
109
Cash and cash equivalents
89
10
76
Deferred tax liabilities
-300
-74
-1 977
Current and non-current financial debts
-1
-32
Current and non-current lease liabilities
-12
-44
Trade payables and other liabilities
-67
-4
-144
Net identifiable assets acquired
1 005
612
7 669
Acquired cash and cash equivalents
-89
-10
-76
Non-controlling interests
-105
Goodwill
161
238
2 580
Net assets recognized as a result of acquisitions of businesses
1 077
735
10 173
Note 2 details significant acquisitions of businesses, specifically of Gyroscope in 2022, the cephalosporin antibiotics business from GSK in 2021; and of the The Medicines Company and the Japanese business of AGI in 2020. The goodwill arising out of these acquisitions is attributable to the buyer-specific synergies, the assembled workforce, and the accounting for deferred tax liabilities on the acquired assets. In 2022, no goodwill (2021: USD 107 million; 2020: USD 74 million) is tax deductible.